Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Controlled, Multicenter Phase 3 Clinical Trial of AK104 for Neoadjuvant/Adjuvant Treatment of Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer

NCT07412613 is registered in ClinicalTrials.gov with Akeso as lead sponsor.

NCT NCT07412613
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07412613 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Controlled, Multicenter Phase 3 Clinical Trial of AK104 for Neoadjuvant/Adjuvant Treatment of Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
Lead sponsor
Akeso
Phase
Phase 3
Overall status
Recruiting
Start date
April 15, 2026
Completion date
March 15, 2031
Enrollment
386 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

msi-h/dmmr colorectal cancer, resectable colon cancer